BridgeBio Pharma's revenue per share for the
three
months ended in Mar. 2025 was $0.61.
BridgeBio Pharma's revenue per share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.67.
Warning Sign:
BridgeBio Pharma Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of BridgeBio Pharma was -45.40% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 35.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 15.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for BridgeBio Pharma's Revenue per Share or its related term are showing as below:
BBIO'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6.6 Med: 10.9 Max: 35.2
Current: 35.2
During the past 8 years, BridgeBio Pharma's highest 3-Year average Revenue Per Share Growth Rate was 35.20% per year. The lowest was -6.60% per year. And the median was 10.90% per year.
BBIO's 3-Year Revenue Growth Rate is ranked better than 81.09% of 788
companies
in the Biotechnology industry
Industry Median: 0.95
vs BBIO: 35.20
BridgeBio Pharma Revenue per Share Historical Data
The historical data trend for BridgeBio Pharma's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BridgeBio Pharma's Revenue per Share
For the Biotechnology subindustry, BridgeBio Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
BridgeBio Pharma's Revenue Per Share for the fiscal year that ended in Dec. 2024 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (NAS:BBIO) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
BridgeBio Pharma Revenue per Share Related Terms
Thank you for viewing the detailed overview of BridgeBio Pharma's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BBIO has been successfully added to your 